ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

(b) On September 29, 2020, Dr. Andrew Satlin notified Intra-Cellular Therapies, Inc. (the "Company") that he would resign from his position as Chief Medical Officer of the Company effective as of October 28, 2020 in order to pursue a new opportunity. Dr. Satlin will assist with the transition of his responsibilities through October 28, 2020. Dr. Satlin's resignation was not the result of any disagreement with the Company or its Board of Directors on any matter relating to the Company's operations, policies or practices.

ITEM 8.01 Other Events.

On October 1, 2020, the Company announced its promotion of Suresh K. Durgam, M.D. to the position of Chief Medical Officer of the Company. Dr. Durgam has served as the Company's Senior Vice President, Late Stage Clinical Development and Medical Affairs since joining the Company in August 2018.

A copy of the press release announcing Dr. Durgam's promotion is attached hereto as Exhibit 99.1.

ITEM 9.01 Financial Statements and Exhibits.




(d) Exhibits



Exhibit
Number       Description

99.1           Press Release of Intra-Cellular Therapies, Inc., dated October 1,
             2020.

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses